Trial record 1 of 1 for:
NCT00081497
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00081497 |
|
Recruitment Status :
Completed
First Posted : April 16, 2004
Results First Posted : August 18, 2010
Last Update Posted : April 2, 2015
|
Sponsor:
Genzyme, a Sanofi Company
Information provided by:
Sanofi
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
People with Fabry Disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to break down and removes certain types of fatty substances called "glycolipids". These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globatriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study analyzed the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease that previously participated in the AGAL-008-00 (NCT0074984) study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fabry Disease | Biological: agalsidase beta | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 67 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study |
| Study Start Date : | January 2004 |
| Actual Primary Completion Date : | September 2005 |
| Actual Study Completion Date : | September 2005 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Fabry disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Fabrazyme 1.0 mg/kg every 2 weeks
This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
|
Biological: agalsidase beta
1.0 mg/kg every 2 weeks
Other Names:
|
Primary Outcome Measures :
- Difference in Inverse Serum Creatinine Within Patients' Slopes Between the Placebo AGAL-008-00 (NCT00074984) and Fabrazyme AGAL02503 (NCT00081497) Periods [ Time Frame: Placebo period AGAL-008-00 (up to 35 months) through Fabrazyme period AGAL02503 (18 months) ]The primary efficacy analysis was the summary of change in slope of inverse serum creatinine for Placebo/Fabrazyme patients in the Intent to Treat (ITT) Population. It compared the placebo period slope with the Fabrazyme period slope.
Secondary Outcome Measures :
- Serum Creatinine at Pre-Fabrazyme and 6, 12, and 18 Months [ Time Frame: Pre-Fabrazyme, 6, 12, and 18 months ]Pre-Fabrazyme=baseline visit of AGAL-008-00 (NCT00074984) for Fabrazyme patients; assessment prior to open-label for placebo patients who transitioned to Fabrazyme in AGAL-008-00 (NCT00074984); assessment prior to first Fabrazyme infusion in AGAL02503 (NCT00081497) for placebo patients who did not transition to Fabrazyme in AGAL-008-00 (NCT00074984).
- Estimated Glomerular Filtration Rate (eGFR) at Pre-Fabrazyme and 6, 12, and 18 Months [ Time Frame: Pre-Fabrazyme, 6, 12, and 18 months ]Pre-Fabrazyme=baseline visit of AGAL-00-800 (NCT00074984) for Fabrazyme patients; assessment prior to open-label for placebo patients who transitioned to Fabrazyme in AGAL-008-00 (NCT00074984); assessment prior to first Fabrazyme infusion in AGAL02503 (NCT00081497) for placebo patients who did not transition to Fabrazyme in AGAL-008-00 (NCT00074984).
- Plasma Globotriaosylceramide (GL-3) (Normal Plasma GL-3 Level is ≤ 7.03 µg/mL) at Pre-Fabrazyme and 6, 12, and 18 Months [ Time Frame: Pre-Fabrazyme and 6, 12, and 18 months ]Pre-Fabrazyme=baseline visit of AGAL00800 for Fabrazyme patients; assessment prior to open-label for placebo patients who transitioned to Fabrazyme in AGAL00800; assessment prior to first Fabrazyme infusion in AGAL02503 for placebo patients who did not transition to Fabrazyme in AGAL00800.
- Proteinuria at Pre-Fabrazyme and 6, 12, and 18 Months [ Time Frame: Pre-Fabrazyme and 6, 12, and 18 months ]Pre-Fabrazyme=baseline visit of AGAL-008-00 (NCT00074984) for Fabrazyme patients; assessment prior to open-label for placebo patients who transitioned to Fabrazyme in AGAL-008-00 (NCT00074984); assessment prior to first Fabrazyme infusion in AGAL02503 (NCT00081497) for placebo patients who did not transition to Fabrazyme in AGAL-008-00 (NCT00074984).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have successfully completed the previous double-blind study AGAL-008-00 (NCT00074984)
- Patients must provide written informed consent prior to study participation
- Female patients of childbearing potential must have a negative pregnancy test prior to each dosing and all female patients must use a medically accepted form of contraception throughout the study
Exclusion Criteria:
- The patient was unable to complete AGAL-008-00 (NCT00074984)
- The patient has undergone kidney transplantation or is currently on dialysis
- The patient has diabetes mellitus or presence of confounding renal disease
- The patient has a clinically significant organic disease or an unstable condition that precludes participation
- The patient is unwilling to comply with the protocol requirements
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00081497
Locations
Show 25 study locations
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
| Study Director: | Medical Monitor | Genzyme, a Sanofi Company |
| Responsible Party: | Medical Monitor, Genzyme Corporation |
| ClinicalTrials.gov Identifier: | NCT00081497 |
| Other Study ID Numbers: |
AGAL02503 |
| First Posted: | April 16, 2004 Key Record Dates |
| Results First Posted: | August 18, 2010 |
| Last Update Posted: | April 2, 2015 |
| Last Verified: | March 2015 |
Keywords provided by Sanofi:
|
alpha-galactosidase A a-GAL r-haGAL |
Fabry GL-3 Fabrazyme |
Additional relevant MeSH terms:
|
Fabry Disease Sphingolipidoses Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders |
Vascular Diseases Cardiovascular Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Metabolism, Inborn Errors Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |